ClinicalTrials.govcontrolled
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or L
ClinicalTrials.gov study NCT03268954. IPD Sharing: YES. Countries: 20. Publications: 1.
ShareScore
40/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 16
- Harmonization
- 12
- Access
- 4
- Reuse readiness
- 0
- Engagement
- 8